Dalbavancin: novel candidate for COVID-19 treatment.

Hoffmann, Markus; Jin, Yeonhwa; Pöhlmann, Stefan

Hoffmann, Markus; Jin, Yeonhwa; Pöhlmann, Stefan.

Hoffmann M; Infection Biology Unit, German Primate Center, 37077, Göttingen, Germany. mhoffmann@dpz.eu.
Jin Y; Faculty of Biology and Psychology, Georg-August-University Göttingen, 37073, Göttingen, Germany. mhoffmann@dpz.eu.
Pöhlmann S; Infection Biology Unit, German Primate Center, 37077, Göttingen, Germany.

Cell Res ; 31(3): 243-244, 2021 03.

Article in English | MEDLINE | ID: covidwho-1039636

Subject(s)

Anti-Bacterial Agents/pharmacology; COVID-19 Drug Treatment; Teicoplanin/analogs & derivatives; Angiotensin-Converting Enzyme 2/metabolism; Animals; Caco-2 Cells; Computer Simulation; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Inflammation; Teicoplanin/pharmacology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Teicoplanin / COVID-19 Drug Treatment / Anti-Bacterial Agents Type of study: Prognostic study Topics: Traditional medicine Limits: Animals / Humans Language: English Journal: Cell Res Year: 2021 Document Type: Article Affiliation country: S41422-020-00459-5

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google